MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2021

    Humor processing is affected by Parkinson’s disease and levodopa

    M. Prenger, K. van Hedger, K. Seergobin, A. Owen, P. Macdonald (London, Canada)

    Objective: This study investigated humor comprehension and appreciation deficits in Parkinson’s disease (PD) as potential non-motor symptoms, and the effect of levodopa on these processes.…
  • MDS Virtual Congress 2021

    Overview of the population of patients with advanced Parkinson’s disease (aPD) initiating therapy with levodopa-carbidopa intestinal gel (LCIG): POMPE-PARK study on French health insurance data (2013-2017)

    JP. Azulay, D. Grabli, S. Benard, N. Kabore, MS. Behier (Marseille, France)

    Objective: To quantify the number of French aPD patients initiating continuous delivery of LCIG from 2013 to 2017 and to describe their demographic, clinical and…
  • MDS Virtual Congress 2021

    LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset

    C. Kwan, I. Frouni, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To investigate the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation on the anti-parkinsonian action of a low dose of…
  • MDS Virtual Congress 2021

    Comparison of gastrointestinal transit times in typical and erratic levodopa-responders in patients with Parkinson’s disease.

    D. Safarpour, B. Brumbach, M. Arena, J. Quinn, J. Nutt, R. Pfeiffer (Portalnd, USA)

    Objective: To determine if altered transit time in the various segments of the gastrointestinal (GI) tract relates to the variability of clinical responses and serum…
  • MDS Virtual Congress 2020

    Orthostatic hypotension in early onset Parkinson’s disease

    Z. Liu, D.N Su, J.H Zhou, T. Feng (Beijing, China)

    Objective: To investigate Orthostatic hypotension (OH)  feature in early onset Parkinson's disease (EOPD)  , especially delayed OH and acute OH post drug.  To explore OH…
  • MDS Virtual Congress 2020

    Motor subtype change between OFF and ON periods in patients with Parkinson’s disease

    O. Esquivel-Zapata, A. Abundes-Corona, F. Herrera-Rodriguez, O. Cardenas-Saenz, E. Escobar-Valdivia, Y. Ríos-Solís, H. Tellez-Lucero, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico, Mexico)

    Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…
  • MDS Virtual Congress 2020

    12-month therapeutic evaluation of l-dopa carbidopa ascorbic acid solution (LCAS) in a cohort of Advanced Parkinson’s disease in a North-Indian tertiary care hospital

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To prescribe LCAS to Parkinson’s disease(PD) patients whose symptoms were not adequately controlled on tablet l-dopa and compare the UPDRS-(I,II,III,IV) ON & OFF on…
  • MDS Virtual Congress 2020

    Sensorimotor inhibition relates to gait dysfunction in people with Parkinson’s disease

    D. Martini, G. Harker, R. Morris, J. Nutt, F. Horak (Portland, OR, USA)

    Objective: To determine how sensorimotor inhibition relates to objective measures of gait OFF and ON levodopa and how having Parkinson’s disease (PD) affects this relationship.…
  • MDS Virtual Congress 2020

    Claims Data Analysis of Parkinson’s Disease Medication Utilization

    M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

    Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…
  • MDS Virtual Congress 2020

    Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation

    M. Soileau, F. Pagan, A. Fasano, R. Rodriguez-Cruz, M. Oh, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, M. Siddiqui (Georgetown, TX, USA)

    Objective: To compare the real-world impact of initiating carbidopa/levodopa enteral suspension (CLES) or deep brain stimulation (DBS) on reducing pill burden (i.e. total number of…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley